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The global epidemic of diabetes mellitus has led to a
continuous increase in the prevalence of diabetic
nephropathy over the past years. Thus, diabetic nephropathy
is currently the number one cause of end-stage renal disease
in the Western world. It represents a major public health
problem for which more effective prevention and treatment
strategies are needed. Thiazolidinediones (TZDs) are a class
of agents that lower blood glucose through reduction of
insulin resistance in patients with type 2 diabetes. Growing
evidence support the concept that TZDs have several
beneficial effects on the cardiovascular system beyond their
effects on glycemic control. These benefits include: blood
pressure lowering, triglyceride reduction, high-density
lipoprotein–cholesterol elevation, and reduction in subclinical
vascular inflammation. Moreover, data from several animal
and human studies support the notion that TZDs reduce
urine albumin excretion and may prevent development of
renal injury. The relative lack of evidence, however,
demonstrating the effects of TZDs on hard renal outcomes
mandates the need for well-designed trials with this
particular objective. This paper summarizes all the data from
clinical and experimental studies relevant to a possible
renoprotective effect of TZDs and discusses actions of these
compounds that may contribute toward this effect.
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The incidence and prevalence of type 2 diabetes mellitus
(DM) has been increasing worldwide since the decade of the
1980s, a rise that is estimated to continue in the future.1,2
Conversely, the incidence of type 1 DM has been stable for
many years.2 Diabetic nephropathy is a common complication
of DM, and represents one of the biggest challenges for modern
nephrology, as it is the most common cause of end-stage renal
disease, accounting for about 40% of all new cases.3,4
The earliest clinical sign of nephropathy in diabetic
patients is the appearance of macroalbuminuria, that is,
urine albumin excretion (UAE) 4300 mg/day, as micro-
albuminuria previously thought to be as an early sign of
nephropathy in type 1 diabetes has been recently shown
not to correlate with the degree of morphologic change in
the kidney.4–6 The presence of microalbuminuria, that is,
UAE between 30 and 300 mg/day is considered a marker
of abnormal endothelial function and increased vascular
permeability7 as well as inflammation,8–10 whereas progres-
sion to macroalbuminuria is a manifestation of overt
nephropathy and associated with faster deterioration of
kidney function.11
The so-called ‘metabolic’ or ‘insulin resistance’ (IR)
syndrome, represents a cluster of disturbances that are risk
factors for cardiovascular disease, including type 2 DM,
abdominal obesity, hypertension, and dyslipidemia,12,13
and its prevalence is today also particularly high in deve-
loped societies.14,15 In the initial descriptions of the
syndrome IR was proposed to be the underlying disorder
of it, causally related to the other components through
various mechanisms.16,17 Several previous studies supported
an association between IR or compensatory hyper-
insulinemia and elevated urine albumin or kidney disease,18
and thus microalbuminuria was proposed to be another main
component of the metabolic syndrome.12
Thiazolidinediones (TZDs) represent a class of com-
pounds currently used for the treatment of type 2 DM that
exert their hypoglycemic properties through reduction of
IR.19,20 These agents act by stimulating a certain type
of nuclear receptor, called peroxisome proliferator-activated
receptor gamma (PPARg). Such receptors are abundant in
adipose tissue cells, but they are also present in various
other cell types, such as vascular smooth muscle cells,
macrophages, vascular endothelial cells, colon epithelial
cells, as well as renal glomerular and tubular cells. Through
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transcriptional regulation of various genes, PPARg receptors
play an important role in adipocyte differentiation and lipid
and carbohydrate metabolism.19,21,22 Apart from improving
glycemic control in patients with type 2 DM, several lines
of evidence support the notion that TZDs have beneficial
effects on other components of the metabolic syndrome,
such as blood pressure (BP) lowering, triglyceride reduction,
high-density lipoprotein–cholesterol elevation, redistribution
of body fat away from the central compartment, decrease
of C-reactive protein and plasminogen activator inhibitor -1
(PAI-1) levels, and others.19,20
Additionally, several animal studies demonstrate that
TZDs also reduce urine albumin or protein excretion and
protect against injury to the kidney.23–26 Moreover, experi-
mental studies exposed numerous actions of TZDs in the
kidney that could explain a possible renoprotective effect.27–32
Human studies also report significant reductions in UAE
among patients with type 2 diabetes by all TZDs examined
(troglitazone, pioglitazone, and rosiglitazone).33–35 This
review summarizes data from clinical and experimental
studies regarding the effect of TZDs on UAE levels, as well as
systemic and local kidney actions of these compounds that
can partly explain a possible renoprotective effect.
EFFECTS OF TZDS ON UAE AND RENAL INJURY
The first indications for a possible renoprotective action of
TZDs came from an animal study with troglitazone more
than 10 years ago, in which this compound was associated
with an important decrease in urine protein excretion,
along with a reduction in BP in obese Zucker rats.23 In
the following years, a beneficial effect on urine albumin
or protein excretion in animal models of IR, diabetes,
and hypertension has been consistently reported for
troglitazone,26,36–39 pioglitazone,24,26,40 and rosiglitazone,25,41,42
whereas troglitazone showed a renal protective effect also in
models of non-diabetic chronic kidney disease43,44 (Table 1).
In many of these studies, this reduction of UAE with TZDs
was accompanied by other beneficial actions on the kidney,
such as reduction of glomerular hyperfiltration, prevention of
intrarenal arteriolosclerosis, and prevention of glomerulo-
sclerosis and tubulointerstitial fibrosis.24–26,38,40,41,43,44 It is
noteworthy, that in studies where TZDs were compared to
angiotensin-converting enzyme (ACE) inhibitors, the TZD
exerted similar43 or superior41 protection against injury to
the kidney.
For almost a decade, several human studies have examined
the renoprotective properties of all TZDs, as shown in
Table 2. In the first among these, Sironi et al.45 found no
significant effect of 200 mg of troglitazone daily on UAE in
patients with type 2 DM, but the baseline levels of UAE in the
group they studied were normal and the study period was
only 8 weeks. In a subsequent study, 400 mg of troglita-
zone were compared to 500 mg of metformin in 30 patients
with type 2 DM and microalbuminuria for 12 weeks.33
Table 1 | Animal studies reporting renal effects of TZDs
Study
TZD
compound Animal model Duration
Effect on urine
albumin or
protein excretion
Effect
on BP
Hemodynamic and morphological
renal effects
Yoshioka
et al.23
Troglitazone Obese Zucker rats 4 and 8 weeks k k NA
Fujii et al.36 Troglitazone Streptozotocin-induced
diabetic rats
12 weeks k ’ NA
Fujiwara
et al.37
Troglitazone Heminephrectomized
Wistar fatty rats
24 weeks k k NA
Isshiki et al.38 Troglitazone Streptozotocin-induced
diabetic rats
12 weeks k NA Prevention of glomerular
hyperfiltration
Nicholas
et al.39
Troglitazone Streptozotocin-induced
diabetic rats
3 months k ’ NA
Yoshida
et al.43
Troglitazone 5/6 nephrectomized SHR 12 weeks ’ k Prevention of glomerulosclerosis
Ma et al.44 Troglitazone 5/6 nephrectomized
Sprague–Dawley rats
12 weeks k ’ Prevention of glomerulosclerosis and
glomerular cell proliferation
Yamashita
et al.26
Troglitazone,
pioglitazone
Streptozotocin-induced
diabetic SHR
12 weeks k ’ Prevention of the loss of anionic sites
of glomerular basement membranes
Yoshimoto
et al.24
Pioglitazone Diabetic Wistar fatty rats 13 weeks k k Prevention of glomerulosclerosis and
intrarenal arteriolosclerosis
Tanimoto
et al.40
Pioglitazone Diabetic KK/Ta mice 4 and 8 weeks k ’ Prevention of glomerular enlargement
Buckingham
et al.25
Rosiglitazone Obese Zucker rats 4 and 9
months
k k Prevention of glomerulosclerosis and
tubulointerstitial fibrosis
Baylis et al.41 Rosiglitazone Obese Zucker rats 6 months k ’ Prevention of glomerulosclerosis and
tubulointerstitial fibrosis
Khan et al.42 Rosiglitazone Obese Zucker rats 12 weeks k k NA
BP, blood pressure; NA, not applicable; SHR, spontaneously hypertensive rats; TZD, thiazolidinedione.
k, significant reduction of urine albumin/protein excretion or blood pressure levels, or protection against elevation of urine albumin/protein excretion or blood pressure
levels observed in untreated groups; ’, no significant effect.
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Troglitazone treatment was associated with a significant
reduction in albumin to creatinine ratio (ACR) of about
40%, whereas metformin treatment had practically no effect.
In another study in 32 type 2 diabetic patients with micro- or
macroalbuminuria but without hypertension, troglitazone
produced a significant reduction in UAE in the microalbu-
minuric group after 12 months of treatment in contrast to
glibenclamide. None of the drugs, however, affected UAE in
the group with macroalbuminuria.46 These findings were not
corroborated as troglitazone was withdrawn from the market
owing to severe hepatotoxicity and rare cases of liver failure
and death.19,47,48
In the first human study of the field with pioglitazone,
Nakamura et al.34 compared the effect of this compound to
glibenclamide and voglibose on 45 normotensive type 2
diabetic patients with microalbuminuria. After 3 months of
treatment, the three drugs produced similar reductions in
hemoglobin A1c (HbA1c) levels, but only pioglitazone
significantly reduced UAE, for about 70%. In a subsequent
study from the same group, pioglitazone was again found to
produce a similar reduction in UAE of type 2 diabetic
normotensive subjects with microalbuminuria.49 Aljabri
et al.50 compared the addition of pioglitazone with that
of bedtime insulin in 62 type 2 diabetic patients already on
metformin and a sulfonylurea. The two treatments produced
a similar reduction in HbA1c levels after 16 weeks, as well as a
similar decrease in the levels of urine ACR. However,
although the authors report no significant differences in
baseline characteristics between groups, patients treated
with pioglitazone had three times lower baseline ACR levels
than those treated with insulin (mean value 58 versus
178 mg/g). Similarly, in another study including 40 type 2
diabetic microalbuminuric patients, pioglitazone signifi-
cantly reduced ACR after 12 weeks, but this decrement was
comparable to that of gliclazide treatment. Again, baseline
ACR levels in the pioglitazone group were about half of those
in the gliclazide group (mean value 55 versus 95 mg/g).51
This beneficial effect of pioglitazone on UAE was also
apparent in larger, multi-center intervention studies, which
compared the general efficacy and safety of this TZD in
comparison with other oral antidiabetic agents in patients
with type 2 DM, the majority of whom had normoalbumi-
Table 2 | Human studies reporting renal effects of TZDs
Study Type of subjects N
Daily doses of regimens
compared Duration
Mean effect on UAE
versus baseline in TZD
groups (%)
Mean effect on
SBP/DBP versus
baseline in TZD
groups (mmHg)
Sironi et al.45 DM2, (hyp)a 40 200 mg Tro versus plb 8 weeks +11% 4/3b
Imano et al.33 DM2, mA, (hyp)a 30 400 mg Tro versus 500 mg Met 12 weeks 39%c 3/0
Nakamura et al.46 DM2, mA or MA 32 400 mg Tro versus 5 mg Gli 12 months 67%c in mA 0% in
MA
6d
Nakamura et al.34 DM2, mA 45 30 mg Pio versus 5 mg Gli versus
0.6 mg Vog
3 months 66%c 6/4
Nakamura et al.49 DM2, mA 28 30 mg Pio versus plb 6 months 59%c 4d
Aljabri et al.50 DM2, (mA)e,
(hyp)a
62 30–45 mg Pio versus isophane
insulin
16 weeks 44% 8/5
Yanagawa et al.51 DM2, mA, (hyp)a 40 Pio versus Met or Gli 12 weeks 45%c NA
Hanefeld et al.52 DM2, (mA)e,
(hyp)a
639 15–45 mg Pio versus
850–2550 mg Met
12 months 15%c NAf
Schernthaner
et al.53
DM2, (hyp)a 1199 15–45 mg Pio versus
850–2550 mg Met
12 months 19%c NAf
Matthews et al.54 DM2, (hyp)a 630 15–45 mg Pio versus 80–320 mg
Gli
12 months 10%c NAf
Agarwal R, et al.55 DM2, MA (hyp)a 44 Pio versus Glip 4 months 7% +3.7/+2.2b
Lebovitz et al.56 DM2, (mA)e,
(hyp)a
493 4 or 8 mg Rosi versus plb 26 weeks 4 mg group: 14%
8 mg group: 22%c
NA
Bakris et al.35 DM2, (mA)e,
(hyp)a
129 8 mg Rosi versus Gli 12 months 30%c 0.1c/2.3b,c
Sarafidis et al.57 DM2, hyp, (mA)e 20 4 mg Rosi 6 months 35%c 5.4c/4.1b,c
Pistrosch et al.58 DM2, (mA)e,
(hyp)a
19 non-mA patients: Rosi versus
Nat, mA patients: Rosi versus
plb
12 weeks non-mA patients:
+18%g, mA patients:
66%c,g
NA
Bakris et al.59 DM2, mA, (hyp)a 389 Rosi versus Gli 32 weeks 23%c 1.3c/2.3b,c
DBP, diastolic blood pressure; DM2, subjects with type 2 diabetes mellitus; Gli, glibenclamide; Glip, glipizide; hyp, subjects with hypertension; mA, subjects with
microalbuminuria; MA, subjects with macroalbuminuria, Met, metformin; NA, changes in blood pressure levels not applicable; Nat, nateglinide; plb, placebo; Pio, pioglitazone;
SBP, systolic blood pressure; Tro, troglitazone; TZd, thiazolidinediones UAE, urine albumin excretion, Vog, Voglibose.
aA percentage of the total population was also hypertensive.
bStudies using ambulatory BP recordings.
cSignificant change versus baseline levels or the other group compared.
dMean change for systolic BP versus baseline in patients treated with the TZD.
eA percentage of the total population had microalbuminuria.
fStudies reporting nonsignificant decreases in BP versus baseline in both the groups compared, without giving detailed changes.
gChange versus the group compared.
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nuria. In one of these studies, Hanefeld et al.52 randomized
more than 600 patients already receiving a sulfonylurea to
pioglitazone or metformin for 52 weeks. Although the two
regimens had comparable effects on glycemic control, urinary
ACR was reduced by 15% in the group receiving pioglitazone
and increased by 2% in metformin group. Another study
from the same group in drug-naive patients with type 2 DM
showed that pioglitazone significantly reduced ACR, whereas
metformin had no effect after 52 weeks of treatment.53 In a
similar follow-up study, the addition of pioglitazone to those
who had previously received metformin therapy was
associated with a decrease in ACR of 10%, whereas the
addition of gliclazide with an increase of 6%. Both drugs,
however, were associated with similar improvements in
glycemic control.54
A recent pilot study evaluated the effect of pioglitazone
and glipizide on urine protein excretion in 44 patients with
overt diabetic nephropathy (median 24-h urine protein 2.6
and 2.8 g/g of creatinine in the two groups, respectively).55
After 4 months of treatment, the pioglitazone group had a
mean adjusted reduction of 7.2% in urine protein excretion,
whereas the glipizide group had an adjusted mean increase
of 6.1%. However, this adjusted mean reduction of 13.2%
with pioglitazone was not statistically significant when
compared to glipizide. These findings are consistent with
the aforementioned data with troglitazone in macroalbumin-
uric patients.46
The effect of rosiglitazone on UAE was originally evaluated
in two multi-center intervention studies in patients with type
2 DM. The first aimed to evaluate the efficacy of rosiglitazone
monotherapy and randomized almost 500 subjects to 2 or
4 mg rosiglitazone b.i.d. or placebo for 6 months.56 Only the
higher dose group showed a significant reduction of 21.6%
versus baseline in ACR. In the subgroup of patients with
microalbuminuria, rosiglitazone reduced ACR by approxi-
mately 40% versus baseline and 30% versus placebo. The
second study was part of a cardiac safety study where
rosiglitazone 4 mg b.i.d. was compared to glyburide in 121
patients for 52 weeks.35 After 28 weeks of treatment, both
groups had significant reductions in ACR of about 30%,
but after 52 weeks only rosiglitazone group continued
to demonstrate a significant ACR reduction. This finding
suggests that duration of follow-up is an important variable
in assessing the effect of TZDs. Additionally, 24-h ambulatory
BP was assessed in this trial and a difference of 3.5/
2.7 mmHg compared to glyburide group was noted at 52
weeks. This change in ambulatory BP correlated with changes
in ACR and less so with HbA1c.
We previously examined the effects of rosiglitazone in a
cohort of patients with both type 2 DM and hypertension.57
After 26 weeks of treatment, the drug reduced UAE,
measured either in 24-h urine collections or with the use of
ACR in spot specimens, by about 35%. In this study, changes
in UAE were positively correlated with changes in ambulatory
systolic BP, diastolic BP, and fasting insulin levels, and
inversely correlated with changes in insulin sensitivity
measured with the hyperinsulinemic euglycemic clamp.
No associations were found between changes in UAE and
changes in fasting glucose or HbA1c. In a separate cross-over
study, rosiglitazone was again shown to reduce UAE in
patients with type 2 DM and microalbuminuria after 12
weeks of treatment, by about 60%.58 Of note in this study
was that rosiglitazone improved renal endothelial nitric oxide
(NO) synthesis and produced also significant reductions of
about 10% in glomerular filtration rate and filtration fraction
in these subjects. This decrease in glomerular filtration
rate was strongly correlated with the respective decrease in
UAE produced by this compound. However, no significant
correlations were found between changes of UAE and
changes of BP, insulin sensitivity, fasting plasma glucose, or
HbA1c with rosiglitazone.
A recent multi-center study examined specifically the
effects on ACR of a TZD or a sulfonylurea compound added
to metformin.59 Three and eighty-nine patients with type 2
DM and microalbuminuria receiving metformin were
randomized to rosiglitazone or glibenclamide. After 32 weeks
of treatment, rosiglitazone was associated with a decrease in
ACR of 23% versus baseline, whereas glibenclamide did not
have any significant effect. As a result, a difference between
treatment groups in ACR of 15% was evident, along with a
difference of about 2.5 mmHg in both 24-h systolic BP and
diastolic BP.
Overall, the above data clearly show that TZD treatment
can reduce UAE. However, it should be emphasized that
currently there are no trials that examine the effects of TZDs
on kidney disease progression, that is, doubling of serum
creatinine or time to onset of end-stage renal disease, in
patients with diabetic nephropathy. Such studies are needed
in order to provide the best evidence for a renoprotective
effect of TZDs.
ACTIONS OF TZDS POSSIBLY CONTRIBUTING TOWARD
A RENOPROTECTIVE EFFECT
The mechanisms through which TZDs reduce UAE and renal
injury are not totally clear at present. Several systemic actions
of TZDs, such as reductions in blood glucose and insulin, as
well as BP levels, could be involved into a renoprotective
property of these compounds. Moreover, functional PPARg
receptors have been identified in renal glomerular and
tubular segments. Expression of PPARg protein is abundant
in inner medulla, that is, the inner medullary collecting
duct and inner medullary interstitial cells.60,61 Various groups
have also identified functional PPARg in cultured animal
glomerular mesangial cells.28,39,62,63 These findings suggest
that TZDs can also protect against renal injury through direct
actions on these receptors. The systemic and local actions
of TZDs possibly involved in a renoprotective effect are
shown in Figure 1.
Reduction in blood glucose and insulin levels
Strict glycemic control is associated with reduction of
microalbuminuria and protection against injury to the
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kidney in patients with DM.64–66 Chronic hyperglycemia is
connected to glomerular dysfunction through mecha-
nisms that include enhancement of the polyol pathway,
non-enzymatic glycation, accumulation of advance-
glycation end products, increase in de novo diacylglycerol
synthesis leading to protein kinase C (PKC) activation and
others.67 Inhibition of PKC has been shown to reduce
albuminuria.27,68,69 TZDs inhibit PKC in various cell types,
including glomerular mesangial cells,27,38,70,71 thus it has
been postulated that troglitazone could reduce UAE through
inhibition of the de novo diacylglycerol-PKC pathway.27,36,38
However, in most of the above studies comparing active
treatments,33–35,46,52–54 although glycemic control was similar
between the different drug groups, UAE was reduced only in
patients receiving a TZD. Moreover, all studies that examined
correlations between changes in UAE and fasting glucose or
HbA1c demonstrated weak or no associations.
35,57,58 Taken
together, these data suggest that improvement in glycemic
control cannot be eliminated as a mechanism by which TZDs
improve UAE, but does not seem to be the only one.
Another possible mechanism for the renoprotective effect
of TZDs is the reduction in elevated insulin levels. In
experimental studies, insulin has been shown to promote
renal injury through various actions, that is, direct induc-
tion of mesangial cell proliferation and extracellular matrix
protein synthesis,72 promotion of insulin-like growth factor I
production,73 which also induces mesangial cell prolifera-
tion,72 increase in renal TGF-b production,74,75 upregulation
of angiotensin II angiotensin 1 receptor mRNA expres-
sion,74,76,77 and stimulation of endothelin-1 production in
mesangial cells.76 Conversely, insulin infusion in vivo
selectively increases renal albumin excretion and clearance
rate in type 2 diabetic patients by about 50%, but not in
healthy subjects.78 In most of the above studies that report
changes in insulin levels, TZD treatment has resulted
in significant reductions in fasting insulin levels in contrast
to other oral antidiabetic agents.33,53,54,57 This decrease
in insulin levels has also been found to correlate with the
reduction of UAE.57 As a result, amelioration of hyperinsu-
linemia with TZDs could be another mechanism contributing
to their renoprotective effects.
BP lowering
Tight BP control is considered even more important than
glycemic control in reducing UAE and protecting
against renal disease progression in patients with type 2
DM and even small variations in BP can play a role in
renoprotection.79,80 A considerable number of previous
animal and human studies have shown that all TZDs
can produce small but significant changes in BP levels and
various TZD actions, such as improvement in endothelial
function, attenuation of sympathetic overactivity, or reduc-
tion of intracellular Ca2þ content in vascular smooth muscle
cells, could be responsible for this effect.81 In many of the
animal studies mentioned above, TZD treatment produced
also significant reductions in BP23–25,37,42,43 (Table 1). In
some of the relevant human studies, changes in BP are not
reported,56 whereas in others BP did not present signi-
ficant changes versus baseline in any of the groups
compared,33,34,46,49,52,53,55,58 as shown in Table 2. However,
in many of the latter studies,33,34,46,49,58 BP changes were
toward different directions (decrease in the groups of TZDs,
increase in the other groups) and no statistical comparison
between the different groups took place. Therefore, the
Reduction of hyperglycemia
Inhibition of glomerular and 
tubular cell proliferation
Improvement in renal 
endothelial function
Blood pressure loweringDecrease of elevated insulin levels
Reduction of inflammatory
processes
Attenuation of the decrease in 
matrix metalloproteinases
Decrease of PAI-1 renal 
expression
Reduction of TGF- and other 
growth factors renal expression 
Decrease of oxidant stress at 
the kidney level
Downregulation of renin–
angiotensin system
Attenuation of renal endothelin-1 
levels and actions
Attenuation of lipid accumulation 
in mesangial cells
Figure 1 | Actions of TZDs possibly contributing to the reduction of UAE and attenuation of renal injury.
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possibility that differences in BP between groups (which
varied up to 10/6 mmHg) have contributed in reductions of
UAE levels with TZDs in these studies cannot be excluded.
Moreover, in most relevant studies that recorded ambu-
latory BP so far, BP was significantly reduced with the TZD
treatment35,57,59 and there were strong and persistent
correlations between the reductions in UAE and BP.
It has to be noted that in both animal models82 and
humans,83,84 reduction of BP with TZD treatment has been
documented even in the presence of fluid retention. Fluid
retention in patients receiving TZDs is a well-documented
observation and has been considered a major contri-
butor toward weight gain, pedal edema, and heart failure
development.84,85 Several mechanisms have been proposed
for this TZD action, including drop in systemic and
intraglomerular BP.82,85 However, recent studies shed more
light on the field, suggesting a PPARg-dependent upregu-
lation of the amiloride-sensitive epithelial Naþ channel in
the collecting duct as the most plausible mechanism.86,87 It
has been observed that treating cultured collecting ducts
with TZDs increased epithelial Naþ channel gene expression
and amiloride-sensitive sodium absorption through a
PPARg-dependent pathway.86 Further, TZDs could not
stimulate sodium transport in collecting duct epithelial cells
with disruption of the PPARg gene.87 In this study, TZDs
could not induce increases in plasma volume and weight
gain in mice with this specific disruption, in contrast to
control animals.86,87 It should be noted, however, that in
clinical studies that examined BP changes, this fluid retention
did not mitigate against BP reduction for up to 1 year.35
Overall, based on existing evidence an even small BP lowering
action of TZDs should be considered as a basic mechanism of
UAE amelioration.
Improvement in endothelial function
Endothelial dysfunction is central in the development
of vascular complications of diabetes and the presence of
microalbuminuria in the urine is considered as the earliest
sign of impaired vascular function at the kidney level.88,89
Numerous experimental and clinical studies have also
established the close relationship between IR and endothelial
dysfunction.90,91 Although the role of renal endothelial
function and NO availability in the progression of diabetic
nephropathy is complex and not totally clear yet, different
abnormalities of NO production contribute to renal injury in
the various stages of the disease.92,93 Amelioration of IR
with TZDs has been shown to improve impaired endothelial
function in patients with type 2 diabetes.94,95 Previous animal
studies support that TZDs can improve impaired renal
NO availability.30,96 Another experimental study suggested
that troglitazone has an endothelium-independent vasodilat-
ing effect on the afferent renal arterioles and a vasodilating
effect on efferent arterioles, leading to reduced capillary
pressure and UAE, which seems to follow an increase in NO
bioavailability.97 Most importantly, the above-mentioned
study from Pistrosch et al.58 has elegantly shown that the
addition of rosiglitazone in microalbuminuric type 2 diabetic
patients simultaneously increased renal NO bioavailability
and reduced hyperfiltration and UAE, suggesting that
improvement in renal endothelial function plays a key role
in TZD-associated renoprotection.
Antiproliferative actions
Growing evidence support a critical role in the pathogenesis
of diabetic nephropathy of several growth factors, the
most important of which seems to be transforming growth
factor-b (TGF-b).98 As mentioned above, insulin was
found to increase TGF-b1 production from mesangial cells74
as well as proximal epithelial renal cells,75 and thus reversion
of hyperinsulinemia with TZDs can also protect against
the increase in renal TGF-b. Troglitazone was previously
associated with inhibition of mesangial cell proliferation
and de-differentiation, inhibition of extracellular matrix
protein increase, as well as promotion of mesangial cell
apoptosis.28,38,62,99 Moreover, TZDs were reported to also
inhibit proliferation and increase apoptosis of renal proximal
tubular cells.100,101 Other experimental studies have
shown that PPARg agonists directly decrease glomerular
TGF-b expression independently of their effects on glucose or
insulin38,44 as well as suppress the glucose-induced produc-
tion of TGF-b from tubular cells.101 TZDs can also inhibit the
TGF-b-induced collagen type 1 and fibronectin synthesis
from mesangial cells.63,102,103 Apart from interference with
TGF-b actions, TZDs have been shown to inhibit prolifera-
tion of mesangial cells induced by other growth factors, such
as platelet-derived growth factor39,104 and vascular endothe-
lial growth factor.105
Other actions of TZDs related to inhibition of growth
procedures at the kidney level are their effects on matrix
metalloproteinases and plasminogen activator inhibitor type
1 (PAI-1) levels. Matrix metalloproteinases are enzymes
normally responsible for glomerular extracellular matrix
degradation and their inhibition leads to extracellular
matrix accumulation and renal fibrosis.106 Pioglitazone was
previously shown to attenuate the decrease of matrix
metalloproteinases-2 and therefore to protect against collagen
IV accumulation in the glomeruli of diabetic rats.32 On the
other hand, PAI-1, a major regulator of fibrinolysis has been
also suggested to influence the progression of diabetic
nephropathy. Although PAI-1 is not expressed in the normal
kidney, renal PAI-1 expression is strongly induced in various
forms of kidney diseases leading to renal failure, as well as in
animals with diabetes even without nephropathy.107,108 In
epidemiological studies, plasma PAI-1 levels were signifi-
cantly correlated with the UAE rate in patients with type 2
DM.109 In terms of pathophysiology, PAI-1, apart from
plasminogen, also inhibits plasmin-mediated matrix metal-
loproteinases activation.107 Inhibition of PAI-1 activity or of
PAI-1 synthesis by specific antibodies, peptidic antagonists,
etc. in vitro was shown to prevent renal fibrosis.107 TZDs
have been repeatedly shown to reduce plasma PAI-1 levels
in humans,110 and to downregulate glomerular PAI-1
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expression, along with a reduction in UAE, in animal
models,39,44 findings indicating another mechanism for their
antifibrotic effects.
Anti-inflammatory actions
During the last years, the association of inflammation
markers with renal function deterioration has been repeat-
edly reported in epidemiological studies and an important
role in the progression of diabetic nephropathy has also been
attributed to inflammatory processes.111,112 TZDs have been
previously shown to suppress the production of proathero-
genic inflammatory cytokines, such as interleukin (IL)-1, IL-
6, and tumor necrosis factor-a from macrophages in vitro113
and to reduce plasma levels of C-reactive protein, the
most common marker of subclinical vascular inflammation,
in type 2 diabetic patients.84,114,115 In renal mesangial cells,
TZDs attenuated the IL-1-mediated increase in the expres-
sion of IL-6 and tumor necrosis factor-a,29 and the stretch-
induced increase in monocyte chemoattractant activity,
by decreasing nuclear factor-kB activation and monocyte
chemoattractant protein-1 production.116 In renal tubular
cells, pioglitazone was shown to reverse the increase in
monocyte chemoattractant protein-1, evoked from low-
density lipoprotein117 and to further suppress monocyte
chemoattractant protein-1 levels after exposure to high
glucose,101 whereas rosiglitazone was reported to reduce the
levels of IL-1, tumor necrosis factor-a, intercellular adhesion
molecule-1, and vascular cell adhesion molecule-1, as well as
the infiltration of renal tissue with macrophages.118 A
reduction in C-reactive protein and IL-6 levels was also
shown in patients with overt diabetic nephropathy treated
with pioglitazone.119
Another possible mechanism of the renoprotective effect
of TZDs is the attenuation of oxidant injury at the kidney
level. Closely linked to inflammatory processes, oxidant stress
is also considered a potent contributor in the progression of
diabetic nephropathy,120 as experimental data indicate an
acceleration of renal injury when normal balance of the
kidney shifts toward a pro-oxidant state and human studies
have shown increased prevalence of oxidant stress both
in patients with early and with overt nephropathy.121,122
Hyperglycemia is a well-known cause of oxidant stress and IR
is also associated with production of free radicals, which in
turn is responsible for a deterioration of insulin action,
leading to a vicious circle.123 Thus, reversion of hyper-
glycemia and IR could lead in amelioration of oxidant stress.
Studies in various animal models suggest that TZDs can act
as a potent general antioxidant124 and reduce oxidative
stress at the kidney level.31,96,125 Although further studies
are necessary in the field, the above data suggest that the anti-
inflammatory and antioxidant properties of TZDs could be
also helpful in renal function protection.
Interference with the renin–angiotensin system
In vitro studies have shown that TZDs can interfere with the
renin–angiotensin system in several tissues. In particular,
Harte et al.126 showed that rosiglitazone lowers the produc-
tion of angiotensins I and II from human subcutaneous
adipocytes, whereas in other studies TZDs have been
found to downregulate the expression of angiotensin 1
receptor mRNA and angiotensin 1 receptor protein in
vascular smooth muscle cells.127,128 These actions of TZDs
could explain other findings regarding their ability to inhibit
angiotensin II-induced vascular smooth muscle cells pro-
liferation.129 These TZDs’ properties should also be examined
in renal glomerular cells, having also in mind the above-
mentioned upregulation of intrarenal renin–angiotensin
system from insulin.74 However, even if this inhibiting
effect of TZDs on renin–angiotensin system actions is
restricted on renal vasculature, it could also contribute to
TZD’s renoprotective properties.
Attenuation of intracellular lipid accumulation
Dyslipidemia has long been proposed as an important
contributor toward the progression of kidney disease and
subsequent evidence from both experimental studies in
animals and clinical studies in humans supported this
notion.130–132 As in the case of atherosclerotic damage, lipid
accumulation and foam cell formation are basic features
of the lipid-mediated glomerular and tubulointerstitial
injury,132,133 and previous studies have shed light to the
mechanisms of lipid uptake and accumulation in renal
cells.134 Emerging evidence suggests that PPARg agonism may
attenuate lipid accumulation and its related injury in
mesangial cells.135,136 Inflammatory cytokines such as IL-1b
are known to promote mesangial lipid accumulation through
dysregulation of low-density lipoprotein receptor expression,
which allows increased lipid uptake,137 as well as inhibition
of cholesterol efflux.135 A reduction of mesangial PPARg
expression was reported to be involved in the last action
of IL-1b, whereas activation of PPARg with the agonist
prostaglandin J2 enhanced lipid efflux and protected
against intracellular lipid accumulation.135 In addition,
liver-X-receptor-a (LXRa), an important regulator of cho-
lesterol efflux in macrophages, has been recently identified in
mesangial cells.136 Activation of LXRa increased cholesterol
efflux, whereas both troglitazone and rosiglitazone were
shown to markedly increase glomerular LXRa expression.136
Taken together, these findings suggest that attenuation of
mesangial lipid accumulation is another possible mechanism
of TZD-associated renoprotection.
Decrease in endothelin-1 levels
Previous studies reported an increase in endothelin-1 levels
in patients with type 2 DM or hypertension and micro-
albuminuria,138,139 suggesting an involvement of endothelin-
1 in the development of nephropathy in these patients.
Insulin has been shown to raise plasma endothelin-1 levels in
vivo in type 2 diabetic subjects140 and to stimulate
endothelin-1 production from endothelial cells,141 as well as
renal mesangial cells76 in vitro. Apart from being a potent
vasoconstrictor of the renal vasculature that reduces renal
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plasma flow and glomerular filtration rate, endothelin-1 has
been shown in experimental studies to have mitogenic
effects on mesangial cells.142,143 Among others, endothelin-1
stimulates a PKC-regulated phospholipase D, which hydro-
lyzes phospholipid substrates and induces generation of
phosphatidic acids that stimulate proliferation in mesangial
cells142 and potentiates the mitogenic effects of angiotensin
II.76 TZDs have been found to significantly reduce urine
endothelin-1 secretion in humans,34 as well as to inhibit PKC
in vitro,27,38,70,71 as mentioned above, indicating that a
depressing action on endothelin-1 levels and the mechanisms
through which endothelin-1 evokes renal injury could also
take part in their renoprotective action.
Other actions of TZDs that can contribute to their
renoprotective properties have also been reported. For
example, PPARg agonists could improve the mechanic
properties of glomerular cells, as they have been found to
reverse the contractile dysfunction of mesangial cells evoked
from hyperglycemia.144 Another mechanism involved in the
reduction in UAE with TZDs could be an increase in
tubular cell albumin uptake, as evident in a recent study.117
Overall, future research should further elucidate actions
like the above or investigate other potential renoprotective
properties of TZDs.
CONCLUSION
The contribution of PPARg agonists to the armamentarium
of treatment of the growing epidemic of patients with type 2
DM provides complementary mechanisms that affect both
glycemic control and inflammatory reactions in this disease.
TZDs act by multiple mechanisms to control glucose and
reduce inflammation and will probably have a role more in
prevention as well as treatment. For now we should use these
agents to reduce inflammatory processes as manifested by
microalbuminuria, as well as improve glycemic control in
patients with type 2 DM.
New strategies for prevention of diabetic nephropathy as
well as the delay of its progression are urgently needed.
Several studies in various animal models have consistently
shown that all TZDs are able to reduce albuminuria as well as
prevent renal injury. Data from human studies in patients
with type 2 DM and normal UAE levels or microalbuminuria
are also promising, as in most of them TZD treatment
significantly reduced UAE. These findings are strongly
supported from both clinical and experimental evidence.
Clearly, TZDs can act beneficially on most of the major
players involved in the progression of diabetic nephropathy,
namely hyperglycemia, hyperinsulinemia, elevated BP, dysli-
pidemia, endothelial dysfunction, inflammatory cytokines,
renin–angiotensin system activation, and others. Hence,
TZDs provide a promising approach for the prevention of
nephropathy in diabetic patients. However, the total
renoprotective effect of TZDs should be explored by future
clinical trials that examine the effects of TZDs in patients
with proteinuria and on harder renal outcomes, like
progressive decline in renal function, as well as by experi-
mental studies investigating the details of the above
protecting mechanisms.
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